Paraoxonase (Pon1) Q192R polymorphism and serum Pon1 activity in diabetic patients on maintenance hemodialysis

Clinical Nephrology

Volumn 60, Issue 4, 2003, Pages 257-265

  Zhang, B ^a   Eto, S ^a   Fan, P ^a   Bian, C ^a   Shimoji, E ^a   Saito, T ^a   Saku, K ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes mellitus; High density lipoprotein; Maintenance hemodialysis; Mutagenically separated PCR; Paraoxonase activity; Q192R polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; SODIUM CHLORIDE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REGULATION; ENZYME SUBSTRATE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MUTAGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PREDICTION; RISK ASSESSMENT;

EID: 0141996273     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp60257     Document Type: Article

References (34)

1. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C 1996 The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 98: 883-885
2. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B 1998 Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18: 1617-1624
3. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN 1998 Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101: 1581-1590
4. Cano NJ, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, Combe C, Fouque D, Laville M, Leverve XM 2002 Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int 62: 593-601
5. Chantrel F, Enache I, Bouiller M, Kolb I, Kunz K, Petitjean P, Moulin B, Hannedouche T 1999 Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 14: 129-136
6. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE 1999 The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 119/120: 429-438
7. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C 1998 Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 9: 2082-2088
8. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE 1996 The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14: 334-336
9. Eckerson HW, Wyte CM, La Du BN 1983 The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35: 1126-1138
10. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J 1997 Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62-66
11. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW 1999 Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19: 2226-2233
12. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K 2000 Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 49: 1400-1405
13. James RW, Leviev I, Righetti A 2000 Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101: 2252-2257
14. Koch M, Hering S, Barth C, Ehren M, Enderle MD, Pfohl M 2001 Paraoxonase 192 Gln/Arg gene polymorphism and cerebrovascular disease: interaction with type 2 diabetes. Exp Clin Endocrinol Diab 109: 141-145
15. Leviev I, James RW 2000 Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20: 516-521
16. Lievre M, Marre M, Chatellier G, Plouin P, Reglier J, Richardson L, Bugnard F, Vasmant D 2000 The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization and patient recruitment. DIABHYCAR Study Group. Control Clin Trials 21: 383-396
17. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJ, Durrington PN 1998 Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin-dependent diabetes mellitus. Atherosclerosis 139: 341-349
18. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM 2001 HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21: 481-488
19. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, Brunzell JD 1996 Paraoxonase genotypes, lipoprotein lipase activity and HDL. Arterioscler Thromb Vasc Biol 16: 1243-1249
20. Paragh G, Seres I, Balogh Z, Varga Z, Karpati I, Matyus J, Ujhelyi L, Kakuk G 1998 The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80: 166-170
21. Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, Haring HU 1999 Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48: 623-627
22. Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J 2001 Paraoxonase2 polymorphisms are associated with nephropathy in type II diabetes. Diabetologia 44: 104-107
23. Richter RJ, Furlong CE 1999 Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9: 745-753
24. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI 2001 Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 354: 1-7
25. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P 1995 Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346: 869-872
26. Rust S, Funke H, Assmann G 1993 Mutagenically separated PCR (MS-PCR): a highly specific one-step procedure for easy mutation detection. Nucleic Acids Res 21: 3623-3629
27. Sakai T, Matsuura B, Onji M 1998 Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern Med 37: 581-584
28. Sanghera DK, Aston CE, Saha N, Kamboh MI 1998 DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 62: 36-44
29. Sanghera DK, Saha N, Aston CE, Kamboh MI 1997 Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17: 1067-1073
30. Sanz Paris A, Lou Arnal LM, Gutierrez Colon JA, Alvarez Lipe A, Albero Gamboa R 1998 Diabetes in hemodialysis: study of differential factors. Ann Med Intern 15: 183-188
31. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ 1996 Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 97: 1630-1639
32. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ 1998 Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287
33. Shinzato T, Nakai S, Akiba T, Yamazaki C, Sasaki R, Kitaoka T, Kubo K, Shinoda T, Kurokawa K, Marumo F, Sato T, Maeda K 1997 Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 12: 884-888
34. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y 1997 A 192 Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17: 3565-3569